Michel Allé, a civil engineer with a master’s degree in economics, has held various managerial positions throughout his career. He has been a manager at the Belgian Science Policy Office, served as a member of the Management Committee of Cobepa (formerly a subsidiary of Paribas), and worked as the CFO of both Brussels Airport and the Belgian Railways. Michel’s academic accomplishments include serving as a professor at the Solvay Brussels School of Economics and Management, where he was also the president from 1997 to 2001.

Michel has been the Chairman of the Board of Ogeda and currently holds director positions at the D’Ieteren Group and Elia Group (both listed), and serves as the Chairman of the Board of Epics Therapeutics.

Denis Bedoret currently serves as Executive Director of Neuvasq Biotechnologies. He is also Director in the Boards of Ncardia, BePharBel, and previously Exothera.

Prior to taking its new role at Neuvasq, Denis was Chief Executive Officer at Imcyse, a clinical-stage biopharmaceutical company committed to advancing the development of a new class of specific immunotherapies to treat auto-immune diseases. Prior to this, he was the CEO of MaSTherCell SA, Belgium and President of MaSTherCell Global Inc., U.S. Under his leadership, the Company expanded significantly growing from 60 to 260 employees and positioning as a leader in the field of CDMO’s dedicated to Cell and Gene therapies products before being acquired by Catalent.

Denis also held the position of Chief Operations Officer at Quality Assistance S.A. a leading European analytical CRO where he was also a member of the Board of Directors. Before that, Denis served as engagement manager at McKinsey & Company, focusing on life science projects.

François Fontaine has served as the General Advisor to the Société Fédérale de Participations et d’Investissements (SFPI) since December 2009. His responsibilities include overseeing investment projects in various sectors, such as new technologies, biomedical, real estate, waste treatment, and water and energy.

Prior to his current role, François worked as an advisor for the tax unit of the Walloon Region where he was responsible for implementing and transferring regional taxes. He holds a Bachelor’s degree in law and tax sciences.

Christina Franssen, PhD, currently an Investment Manager at WE Life Sciences, brings over two decades of experience in innovation and research to her role. Prior to joining WE Life Sciences in 2019, Christina served as Business Development Manager and later Director of State-of-the-Art Technology Platforms at GIGA, a research institute associated with the University of Liège.

Christina started her career as a research scientist and went through the full cycle of entrepreneurship, founding a spin-off company, and leading it to a successful exit. She holds a Master’s degree in Biology and a PhD in Microbiology & Genetics from the Université de Liège (Belgium).

Pierre Detrixhe is Managing Partner at Financière spin-off luxembourgeoise and Venture Director at Newton Biocapital. He brings more than 10 years of experience in the field of venture capital and has accompanied many companies in the start-up phase. Previously, he held positions of scientist and technology transfer officer in the biotechnology field.

Pierre Detrixhe is Director at the Board of some promising Belgian start-up companies. He holds a Master in Bioengineering from the University of Liège (Gembloux Agro-Bio Tech), Belgium and a Master in Management from the Catholic University of Louvain, Belgium.

Dr. Yves Ribeill, PhD, currently works as a Partner and Entrepreneur in Residence at Argobio Studio in Paris, France. He is a seasoned entrepreneur who founded Scynexis, Inc (NASDAQ: SCYX) and served as its President from 1999 to 2015, as well as its Chief Executive Officer from 1999 to 2015. Prior to his tenure at Scynexis, Inc., he held various positions at Rhone-Poulenc, Aventis, where he spent 20 years of his international career and served as Director of Chemistry for the Anti-Infective Group.

Throughout his career, he has played a key role in the development and FDA approval of numerous drugs at Rhone-Poulenc and Scynexis. He has also served on the board of directors for various biotech companies in Europe and the US, and currently chairs the board of Calyxt (NASDAQ:CLXT). Dr. Ribeill holds a Ph.D. in Chemistry from the University of Montpellier (France) and has authored over 26 publications and 17 patents.

He is a member of the Scientific Advisory Board of DNDi, and has previously served on the Scientific Advisory Committee of the World Health Organization and the Medicine Malaria Venture in Geneva.